Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000629324 | SCV000750259 | benign | Primary ciliary dyskinesia | 2024-10-30 | criteria provided, single submitter | clinical testing | |
Eurofins Ntd Llc |
RCV000734391 | SCV000862530 | uncertain significance | not provided | 2018-07-18 | criteria provided, single submitter | clinical testing | |
New York Genome Center | RCV001542426 | SCV001761128 | uncertain significance | Primary ciliary dyskinesia 7 | 2020-06-26 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000629324 | SCV004858247 | uncertain significance | Primary ciliary dyskinesia | 2023-11-03 | criteria provided, single submitter | clinical testing | The c.10631A>G (p.E3544G) alteration is located in exon 65 (coding exon 65) of the DNAH11 gene. This alteration results from a A to G substitution at nucleotide position 10631, causing the glutamic acid (E) at amino acid position 3544 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |